ARS Pharmaceuticals to Participate in a Major Healthcare Event
SAN DIEGO — ARS Pharmaceuticals, Inc. (Nasdaq: SPRY) will join the 2024 Cantor Global Healthcare Conference, taking place September 17–19. The gathering offers a timely stage for ARS Pharma to meet with investors and highlight its work in health management, with a clear focus on severe allergic reactions that can escalate to anaphylaxis.
Who’s Representing ARS Pharmaceuticals
Two company leaders will speak for ARS Pharma during the event: Co-Founder, President, and CEO Richard Lowenthal, and Chief Commercial Officer Eric Karas. They’re set to appear in a fireside chat on Tuesday at 9:10 a.m. ET, where they’ll discuss how the company is approaching allergy care and the ways it aims to support both patients and caregivers. In addition to the session, the team will hold one-on-one meetings with investors, underscoring ARS Pharma’s commitment to ongoing dialogue with the investment community.
Inside the Fireside Chat
The conversation will touch on ARS Pharma’s current initiatives and its lead product, neffy®, an epinephrine nasal spray intended for immediate use during Type I allergic reactions. The session will be streamed by webcast so the broader public can listen in, offering anyone interested a window into the company’s thinking on allergy preparedness and response.
A Closer Look at neffy®
neffy® (marketed as EURneffy in the EU) reflects ARS Pharmaceuticals’ focus on addressing anaphylaxis quickly and directly. Designed to provide rapid relief in the face of severe allergic reactions, it offers an option for people who may encounter life-threatening reactions to common triggers, including certain foods or insect stings.
Why Access to This Option Matters
As an innovative way to deliver epinephrine, neffy® aims to put fast, effective treatment within reach. For anyone with a history of serious allergies—and for those who care for them—having a reliable option on hand can make all the difference when seconds count. ARS Pharmaceuticals, Inc. is working to advance these life-saving solutions through better preparedness and support.
Vision and Priorities
ARS Pharmaceuticals’ goal is straightforward: help people stay safer and more in control of their health. With neffy® as a cornerstone, the company is extending its reach into additional markets while continuing to engage at high-profile forums like the Cantor conference. The team’s near-term focus is ensuring investors understand the scale of need in allergy management and how ARS Pharma is positioned to meet it. The broader aim remains the same—meaningful impact in medical care, grounded in practical, patient-centered tools.
How to Connect with ARS Pharmaceuticals
ARS Pharmaceuticals invites ongoing engagement from stakeholders of all kinds. If you’re an investor evaluating the opportunity around neffy® or a healthcare professional seeking to better support patients, the company welcomes the conversation. For inquiries, Investor Relations contact Justin Chakma can provide additional context and details.
Frequently Asked Questions
What’s the goal of the 2024 Cantor Global Healthcare Conference for ARS Pharmaceuticals?
It’s a forum to present the company’s work, meet with investors, and discuss progress in healthcare—especially around managing severe allergic reactions and anaphylaxis.
Who will speak for ARS Pharmaceuticals, and when is the session?
Co-Founder, President, and CEO Richard Lowenthal and Chief Commercial Officer Eric Karas will appear in a fireside chat on Tuesday at 9:10 a.m. ET.
What is neffy®, and when is it used?
neffy® is an epinephrine nasal spray intended for immediate use during Type I allergic reactions. It’s designed to offer fast help in situations that may lead to anaphylaxis.
How can I watch the fireside chat?
The discussion will be streamed via a live webcast that’s accessible to the public and linked from the Investors & Media section of ARS Pharmaceuticals’ website.
Who should I contact for more information?
For investor-related questions, reach out to Justin Chakma at ARS Pharmaceuticals. You can also visit the company’s official website for additional information.
